Ultimovacs ASA Statistics

Total Valuation

Ultimovacs ASA has a market cap or net worth of NOK 94.27 million. The enterprise value is -73.12 million.

Market Cap	94.27M
Enterprise Value	-73.12M

Important Dates

The next estimated earnings date is Wednesday, November 6, 2024.

Earnings Date	Nov 6, 2024
Ex-Dividend Date	n/a

Share Statistics

Ultimovacs ASA has 34.41 million shares outstanding. The number of shares has increased by 0.20% in one year.

Shares Outstanding	34.41M
Shares Change (YoY)	+0.20%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	1.27%
Owned by Institutions (%)	17.78%
Float	23.60M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
PB Ratio	0.43
P/FCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	0.41
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	0.41

Financial Position

The company has a current ratio of 7.84, with a Debt / Equity ratio of 1.38.

Current Ratio	7.84
Quick Ratio	7.80
Debt / Equity	1.38
Debt / EBITDA	n/a
Debt / FCF	-0.02
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is -59.69% and return on invested capital (ROIC) is -38.70%.

Return on Equity (ROE)	-59.69%
Return on Assets (ROA)	-34.12%
Return on Capital (ROIC)	-38.70%
Revenue Per Employee	n/a
Profits Per Employee	-7.79M
Employee Count	27
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -96.19% in the last 52 weeks. The beta is 1.09, so Ultimovacs ASA's price volatility has been similar to the market average.

Beta (5Y)	1.09
52-Week Price Change	-96.19%
50-Day Moving Average	6.15
200-Day Moving Average	55.22
Relative Strength Index (RSI)	22.44
Average Volume (20 Days)	629,452

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-188.30M
Pretax Income	-179.27M
Net Income	-179.27M
EBITDA	-187.38M
EBIT	-188.30M
Earnings Per Share (EPS)	-5.21

Full Income Statement

Balance Sheet

The company has 170.40 million in cash and 3.01 million in debt, giving a net cash position of 167.39 million or 4.87 per share.

Cash & Cash Equivalents	170.40M
Total Debt	3.01M
Net Cash	167.39M
Net Cash Per Share	4.87
Equity (Book Value)	217.46M
Book Value Per Share	6.32
Working Capital	155.40M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -179.82 million and capital expenditures -17,000, giving a free cash flow of -179.83 million.

Operating Cash Flow	-179.82M
Capital Expenditures	-17,000
Free Cash Flow	-179.83M
FCF Per Share	-5.23

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Ultimovacs ASA does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-0.20%
Shareholder Yield	-0.20%
Earnings Yield	-190.18%
FCF Yield	-190.76%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a